By Daniel Wilson ( August 9, 2012, 4:39 PM EDT) -- The U.S. Food and Drug Administration has accused Forest Laboratories Inc. of allowing two sales representatives to push its chronic obstructive pulmonary disease drug Daliresp for off-label use, despite a promotional integrity agreement reached with the agency as part of a $313 million off-label marketing settlement....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.